| Wissenschaftl. Titel | A Phase 3, Open label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an anti CD20 × anti-CD3 bispecific antibody, in Combination with CHOP (O-CHOP) versus Rituximab in combination with CHOP (R-CHOP) in Previously Untreated Participants with Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3) |
| Erkrankung |
Haema:
NHL: diffuses, großzelliges B-Zell-Lymphom:
Erstlinie
|
| Molekularer Marker |
CD20+ |
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (MZ) Weiterführende Informationen (NIH) |
erstellt 29.07.2024 Data entry III CCP
geändert 29.07.2024 Data entry III CCP